- Email: [email protected]
Modified Pasteurella bacteria and vaccines prepared therefrom-chemical modification of virulent Pasteurella multocida and Pasteurella haemolytica using acriflavine HCI
Patent Report Propagation of hemorrhagic-enteritis virus - in turkey lymphoblastoid cell line; use for vaccine production US. Sect. Agr. US 4, 388, 298; 14 June 1983
A lymphoblastoid cell line of turkey origin, designated MDTC-RP-19 (ATCC CRL-8135), is used for the in vitro propagation of hemorrhagic-enteritis virus (HEV). The inoculated cell suspension is repeatedly serially passaged and cultured until practically all the cells are infected with HEV, whereupon the supernatant fluid is collected for vaccine production. Both virulent and apathogenic isolates of HEV may be cultured in this manner. 023-83
Modified Pasteurella bacteria and vaccines prepared therefrom- chemical modification of virulent Pasteurella multocida and Pasteurella haemolytica using acriflavine HCI Norden US 4, 388, 299
Modified live Pasteurella haemolytica ATCC 31611 or Pasteurella multocida ATCC 31609 vaccine capable of inducing immunity in cattle, pigs and sheep without serious side-effects, comprises live P haemolytica or P multocida modified with an acridinium salt, preferably acriflavine HCI. The organisms are passaged up to 40 times in the acridinium salt-supplemented broth. Vaccines are prepared by conventional methods, for example by combining the bacteria with a suitable carrier and/or a stabilizer. 024-83
A method of stimulating macrophages in vivo in a host which comprises administering to said host an immunostimulant effective amount of a biologically active composition which comprises a biologically acceptable carrier and a peptide which is effective for stimulating macrophages in vivo having a prolyl---prolyl--*glycyl sequence and a maximum of seven aminoacyl residues. 025-83
Preparations of purified bacterial membranai proteoglycans Pierre Fabre SA. US 4, 397, 838; 9 August, 1983
An immunity adjuvant for vaccines comprising purified water-soluble proteoglycans obtained by a process which comprises at least one step in which crude membranal proteoglycans ofKlebsMla, Serratia or Escherichia are treated in an aqueous medium with a reactant selected from the group consisting of bases and hypobromites followed by removal of the excess reactant and the insoluble residue, said purified water-soluble proteoglycans. A vaccine based on bacterial ribosome and/or RNA as immunogenic agent containing as immunity adjuvant an effective amount of an adjuvant of the type set forth above. 026-83
Adult schistosome worm-derived antigenic substance and method of obtaining same L Messineo et al. US 4, 396, 600; 2 August 1983
Peptides having immunostimulating properties and pharmaceutical compositions containing them Inst. Pasteur US 4, 399, 124; 16 August 1983
An antigen-containing extractant capable of developing an immune reaction in mammals to infection by schistosomes comprising a saline extract obtained from live adult schistosomes. 027-83
Keep up to date with all research in the field
read
DERWENT BIOTECHNOLOGY ABSTRACTS •
In-depth coverage of all aspects of biotechnology
•
Current awareness through rapid publication
•
Around 1,0OO publications scanned
•
Data classified and fully indexed
•
World-wide patents literature
•
Online retrieval
Please contact your nearest Derwent Office for further information, subcription details, and FREE SAMPLE COPY
D E R W E N T - - World Leader in Scientific and Patents Documentation DERWENT PUBLICATIONS LTD, ROCHDALE HOUSE, 128 THEOBALDS ROAD, LONDON WC1X 8RP. ENGLAND TEL. (01) 242-5823 TLX. 267487 DERWENT INC. SUITE 500, 6845 ELM ST. MC.LEAN VA 22101 USA TEL. (703) 790-0400 REPRESENTATIVE FOR JAPAN, NIPPON GIJUTSU BOEKI CO. LTD, KASUMIGASEKI BLDG. 32 F. 2-5 KASUMIGASEKI 3-CHROME, CHIYODA-KU, TOKYO 100
52
Vaccine, Vol. 1, December 1983
A lymphoblastoid cell line of turkey origin, designated MDTC-RP-19 (ATCC CRL-8135), is used for the in vitro propagation of hemorrhagic-enteritis virus (HEV). The inoculated cell suspension is repeatedly serially passaged and cultured until practically all the cells are infected with HEV, whereupon the supernatant fluid is collected for vaccine production. Both virulent and apathogenic isolates of HEV may be cultured in this manner. 023-83
Modified Pasteurella bacteria and vaccines prepared therefrom- chemical modification of virulent Pasteurella multocida and Pasteurella haemolytica using acriflavine HCI Norden US 4, 388, 299
Modified live Pasteurella haemolytica ATCC 31611 or Pasteurella multocida ATCC 31609 vaccine capable of inducing immunity in cattle, pigs and sheep without serious side-effects, comprises live P haemolytica or P multocida modified with an acridinium salt, preferably acriflavine HCI. The organisms are passaged up to 40 times in the acridinium salt-supplemented broth. Vaccines are prepared by conventional methods, for example by combining the bacteria with a suitable carrier and/or a stabilizer. 024-83
A method of stimulating macrophages in vivo in a host which comprises administering to said host an immunostimulant effective amount of a biologically active composition which comprises a biologically acceptable carrier and a peptide which is effective for stimulating macrophages in vivo having a prolyl---prolyl--*glycyl sequence and a maximum of seven aminoacyl residues. 025-83
Preparations of purified bacterial membranai proteoglycans Pierre Fabre SA. US 4, 397, 838; 9 August, 1983
An immunity adjuvant for vaccines comprising purified water-soluble proteoglycans obtained by a process which comprises at least one step in which crude membranal proteoglycans ofKlebsMla, Serratia or Escherichia are treated in an aqueous medium with a reactant selected from the group consisting of bases and hypobromites followed by removal of the excess reactant and the insoluble residue, said purified water-soluble proteoglycans. A vaccine based on bacterial ribosome and/or RNA as immunogenic agent containing as immunity adjuvant an effective amount of an adjuvant of the type set forth above. 026-83
Adult schistosome worm-derived antigenic substance and method of obtaining same L Messineo et al. US 4, 396, 600; 2 August 1983
Peptides having immunostimulating properties and pharmaceutical compositions containing them Inst. Pasteur US 4, 399, 124; 16 August 1983
An antigen-containing extractant capable of developing an immune reaction in mammals to infection by schistosomes comprising a saline extract obtained from live adult schistosomes. 027-83
Keep up to date with all research in the field
read
DERWENT BIOTECHNOLOGY ABSTRACTS •
In-depth coverage of all aspects of biotechnology
•
Current awareness through rapid publication
•
Around 1,0OO publications scanned
•
Data classified and fully indexed
•
World-wide patents literature
•
Online retrieval
Please contact your nearest Derwent Office for further information, subcription details, and FREE SAMPLE COPY
D E R W E N T - - World Leader in Scientific and Patents Documentation DERWENT PUBLICATIONS LTD, ROCHDALE HOUSE, 128 THEOBALDS ROAD, LONDON WC1X 8RP. ENGLAND TEL. (01) 242-5823 TLX. 267487 DERWENT INC. SUITE 500, 6845 ELM ST. MC.LEAN VA 22101 USA TEL. (703) 790-0400 REPRESENTATIVE FOR JAPAN, NIPPON GIJUTSU BOEKI CO. LTD, KASUMIGASEKI BLDG. 32 F. 2-5 KASUMIGASEKI 3-CHROME, CHIYODA-KU, TOKYO 100
52
Vaccine, Vol. 1, December 1983